Innovation partnerships
At Genoskin, innovation thrives through collaboration
Our vision for collaborative innovation
Our mission to provide cutting-edge, human-relevant skin models is powered by a strong ecosystem of partnerships with academic institutions, public agencies, industry leaders, and biotech pioneers. Together, we’re shaping the future of dermatological, immunological, and therapeutic research.
We believe that impactful science starts with strong partnerships. By joining forces with public and private organizations, Genoskin co-develops technologies that enhance drug and cosmetic development, improve predictive modeling, and reduce reliance on animal testing. From early research to applied product validation, we partner at every stage of the innovation journey. Types of partnerships we support:
Multi-partner grant-funded R&D projects
Bilateral academic collaborations
Commercial model co-development
Clinical validation & preclinical testing studies
Academic roots, global reach
Founding collaborations
Genoskin was born out of a pioneering academic initiative between CNRS, Paul Sabatier University, and Toulouse University, and we continue to collaborate on advanced research in skin biology and immunology. The company’s growth and innovation have been made possible by a broad network of public and institutional supporters. These organizations have provided funding, mentorship, infrastructure, and international visibility at key moments in our journey.
Public support & recognition
We’ve been supported by key French and European institutions that recognized our potential to transform skin model research.
“From academia to global biotech, Genoskin’s journey is proof that bold ideas, nurtured through strong partnerships, can become industry-transforming platforms.”
Industry, academic & accelerator partnerships
Genoskin thrives at the intersection of science, innovation, and collaboration. Over the years, we’ve built a strong ecosystem of partners across industry, academia, and startup acceleration networks to bring breakthrough skin models to life.
Industry collaborations
We work with leading pharmaceutical, biotech, and cosmetic companies to co-develop customized skin models tailored to R&D and regulatory needs. These partnerships have helped validate applications such as:
Academic engagement
We proudly support the global research community by offering preferential access to our models for fundamental and translational skin biology studies. Our platforms are regularly used in peer-reviewed publications covering inflammation, wound healing, and metabolic processes.
Business acceleration support
Genoskin’s early success was supported by several prestigious programs that provided strategic resources and infrastructure:
Did you know?
These programs offered more than funding, they opened doors to networks, tools, and international exposure that helped us scale quickly and strategically.
Our HypoSkin® model, developed with support from the European Union Horizon 2020 program, is now a reference tool for assessing responses to injectable drugs.
Collaborative R&D projects
At Genoskin, collaboration is in our DNA
Since day one, we’ve worked hand-in-hand with global leaders in the biopharma, chemical, and cosmetics industries to push the boundaries of skin research. Together, we develop cutting-edge human skin models that deliver real, predictive data—helping bring better therapies and products to market faster.
We’re also proud to support academic research by offering preferential access to our skin platforms for labs exploring everything from skin metabolism to complex disease mechanisms. Whether you’re looking to study immune responses, test new compounds, or develop a completely new skin model, we’re always open to exciting new partnerships.
Have an idea or research question? We partner with research institutes and industry leaders through multi-partner, grant-funded projects to co-develop the next generation of human skin models. Let’s team up to shape the future of skin science.
Our collaborative research projects combine the strengths of academic science and industry-driven innovation. These multi-stakeholder efforts tackle complex challenges in skin biology, immunology, and therapeutic development.
MICCA – Harnessing the microbiome to treat age-related alopecia
Project Summary
Hair thinning and loss due to aging—also known as age-related alopecia—affects millions of individuals worldwide and significantly impacts quality of life. Traditional treatments often fall short in efficacy, sustainability, or safety. The MICCA (Microbiome & Communication of Cells in Alopecia) project takes a scientific leap forward by focusing on the biological dialogue between hair follicle cells and the skin microbiome, which plays a key role in maintaining hair health and preventing hair loss.
Project partners
• Lead Partner: SISLEY France (cosmetics innovation leader)
• Consortium Members: SEDERMA (active ingredient developer), Laboratory of Microbiology Signals & Microenvironment (academic partner), and Genoskin
• Funding: €2.3 million total, with €436,940 in French state aid and €594,399 from Regions Occitanie and Normandie
• Focus: Use of natural ingredients to improve communication between hair follicles and the microbiome to treat age-related alopecia.
“The MICCA project exemplifies the power of collaborative research. By uniting biotech, cosmetics, and microbiome science, we’re moving beyond surface treatments to target the biological root of hair loss.”
Project Coordinator, SISLEY France
Genoskin’s role
Genoskin contributes extensive expertise in human skin biology to develop novel ex vivo and in vitro hair models that incorporate both follicular structures and microbiome components. These models offer a human-relevant, immunocompetent testing environment for evaluating how natural compounds affect cellular communication under inflammatory conditions.
Our platform allows project partners to:
Scientific objectives
Methodology
The project uses:
• Inflammatory stimulation models to mimic hair loss conditions
• Microbiome-integrated ex vivo skin systems for accurate response tracking
• Biomarker profiling to assess efficacy of plant-based and biotechnological ingredients
Anticipated outcomes
Plasmaregen – Pioneering cold atmospheric plasma (CAP) for wound healing
Project summary
Chronic and pathological wounds continue to challenge modern medicine, often leading to high morbidity and prolonged hospital stays. While cold atmospheric plasma (CAP) has shown promise in reducing microbial load and promoting tissue regeneration, its mechanisms of action remain poorly understood. The Plasmaregen project sets out to provide the first comprehensive preclinical data on how CAP interacts with skin cells, tissue, and the wound healing process.
Scientific background
Wound healing involves a cascade of complex molecular events. CAP technology has been shown to:
• Sterilize infected wounds
• Modulate inflammation
• Accelerate cell proliferation and re-epithelialization
Yet, clinical trials remain sparse, and validated models to study CAP’s biological impact are lacking. That’s where Genoskin comes in.
Project objectives
Genoskin’s role
Genoskin provides a robust human ex vivo skin model to evaluate:
• Cellular viability and tissue structure post-CAP exposure
• Inflammatory biomarker response
• Healing dynamics in wounded skin tissue
These experiments allow project partners to distinguish between safe therapeutic doses and potential cytotoxic thresholds, offering essential insights before moving into clinical phases.
Methodology
• Expose wounded skin models to predefined CAP profiles
• Use advanced imaging and histological analysis to assess regeneration
• Employ electrochemical sensors to measure reactive species in situ
Anticipated outcomes
• First-of-its-kind preclinical data on CAP’s effects in human skin
• New electrochemical biosensors for clinical plasma therapy studies
• Foundational safety and efficacy guidelines for future plasma-based devices
